Brian Stephenson Acquires 6,250 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson purchased 6,250 shares of Sensei Biotherapeutics stock in a transaction that occurred on Friday, June 26th. The stock was purchased at an average price of $24.95 per share, with a total value of $155,937.50. Following the completion of the purchase, the chief financial officer directly owned 33,054 shares in the company, valued at $824,697.30. This trade represents a 23.32% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sensei Biotherapeutics Trading Down 7.3%

FTH stock traded down $1.80 during trading hours on Friday, hitting $22.87. 145,732 shares of the stock were exchanged, compared to its average volume of 82,691. Sensei Biotherapeutics, Inc. has a 12 month low of $6.32 and a 12 month high of $36.76.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HC Wainwright initiated coverage on shares of Sensei Biotherapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 price target on the stock. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a report on Friday. They issued an “outperform” rating and a $57.00 price objective for the company. Finally, Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.